4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Kardigan, Inc. (KARD) operates in the Biotechnology industry and is headquartered in Princeton, United States with about 241 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, KARD reported $0M in revenue and ($192M) in net income.
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Revenue | $0M | $0M |
| Operating Income (EBIT) | ($202M) | ($97M) |
| Net Income | ($192M) | ($89M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Total Revenue | $0M | $0M |
| Operating Income (EBIT) | ($59M) | ($26M) |
| Net Income | ($56M) | ($18M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Assets | $391M | $64M |
| Total Liabilities | $641M | $147M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KARD viewer.
About TickerBase · Data methodology & sources